CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 346 enrolled
Drug / intervention
insulin degludec +2 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01664247
NCT01664247Phase 3Completed
CompareCT.gov

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Novo Nordisk A/S·interventional·Posted Aug 14, 2012·Updated Sep 25, 2017

In Brief

A Phase 3 clinical trial evaluating insulin degludec, placebo, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 346 participants across 132 sites in 11 countries.

Detailed Summary

This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with type 2 diabetes qualifying for treatment intensification.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCanada, France, Germany, Israel, Italy, Serbia, South Africa, Ukraine, United Arab Emirates, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 14, 2012
Enrollment StartOct 1, 2012
Primary CompletionDec 31, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.9 years ago

Interventions

insulin degludecdrug

Administered s.c. (under the skin) once daily. Dose individually adjusted.

placebodrug

Administered s.c. (under the skin) once daily. Dose individually adjusted.

liraglutidedrug

Administered s.c. (under the skin) once daily. Dose: 1.8 mg.